National Bank of Canada’s Elicio Therapeutics ELTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$391 Buy
+1
New +$10 ﹤0.01% 2892

Other funds holding ELTX

National Bank of Canada's ELTX Position: Q2 2026 in Review

National Bank of Canada opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 100 shares worth $391. The stake represents ﹤0.01% of the portfolio and ranks #2891 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in ELTX as recently as Q3 2024.

National Bank of Canada first reported a position in ELTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $6.5K in Q1 2024. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • National Bank of Canada held 100 shares of Elicio Therapeutics worth $391 as of Q2 2026.
  • Elicio Therapeutics was a new National Bank of Canada position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2891 holding.
  • National Bank of Canada first reported a position in Elicio Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • National Bank of Canada's Elicio Therapeutics position peaked at $6.5K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.